research use only
Cat.No.S6872
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease |
|---|---|
| Other 3C-Like Protease Inhibitors | GC376 |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 752.68 | Formula | C20H10Br2HgO6.2Na |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 129-16-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Mercurochrome, Merbromine, Mercurocol, Sodium mercurescein, Asceptichrome, Supercrome, Brocasept, Cinfacromin | Smiles | C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=C(C(=C(C=C24)Br)[O-])[Hg])Br)C(=O)[O-].O.[Na+].[Na+] | ||
| Targets/IC50/Ki |
3C-Like Protease
|
|---|---|
| In vitro |
Merbromin strongly inhibites the proteolytic activity of 3CLpro which is a promising target for developing anti-SARS-CoV-2 drugs. Michaelis-Menten kinetic analysis shows that this compound is a mixed-type inhibitor of 3CLpro, indicating by its ability of increasing the KM and decreasing the Kcat of 3CLpro. And 3CLpro possessed two binding sites for this chemical. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.